Structure knows best

Although most of Heptares' compounds are against clinically validated targets, and only one currently boasts first-in-class potential, the structure-based drug design company is building a case for its ability to expand targets into new indications, or improve upon the efficacy and/or safety profiles of more advanced candidates.

In the wake of being acquired by Sosei Group Corp. in February, Heptares landed new partner AstraZeneca plc this month, with the pharma taking an exclusive, worldwide license to the biotech's HTL1071 immuno-oncology program...